![His six-month “listening tour” almost over, Sharpless discusses his vision for NCI](https://cdn.cancerletter.com/media/2018/02/sharpless-web.jpg)
![His six-month “listening tour” almost over, Sharpless discusses his vision for NCI](https://cdn.cancerletter.com/media/2018/02/sharpless-web.jpg)
Cover Story
Conversation with The Cancer LetterFree
“The notion that cancer's not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.
In Brief
Clinical Roundup
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI trials for February
NCI trials for FebruaryThe National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.